Nevers, France

Cécile Bougeret


 

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Le Vesinet, FR (2013)
  • Nevers, FR (2016 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Cécile Bougeret: Innovator in Cancer Treatment

Introduction

Cécile Bougeret is a prominent inventor based in Nevers, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for cancer and other diseases. With a total of 6 patents to her name, her work is paving the way for new therapeutic options.

Latest Patents

Among her latest patents, Cécile has developed piperazinyl derivatives for the treatment of cancer. These derivatives, characterized by their unique formula, are disclosed for their potential use as a drug, particularly in oncology. Additionally, she has introduced a new class of indole derivatives aimed at treating cancer, viral infections, and lung diseases. These indole derivatives exhibit a specific MKlp2 inhibition profile, making them valuable therapeutic agents.

Career Highlights

Cécile has worked with notable companies in the pharmaceutical sector, including Biokinesis. Her innovative research and development efforts have positioned her as a key figure in the fight against cancer and other serious health conditions.

Collaborations

Cécile has collaborated with esteemed colleagues such as Denis Carniato and Mathieu Gutmann. Their combined expertise has contributed to the advancement of her research and the successful development of her patented inventions.

Conclusion

Cécile Bougeret's work exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions to cancer treatment through her patented inventions highlight her dedication to improving health outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…